Volume 72, Issue 15 pp. 1678-1687
Original Article

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth

Christian Ruiz

Christian Ruiz

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Martin Oeggerli

Martin Oeggerli

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Markus Germann

Markus Germann

Department of Clinical Research, Urology Research Laboratory, Inselspital Bern, University of Bern, Bern, Switzerland

Search for more papers by this author
Silvia Gluderer

Silvia Gluderer

Institute of Molecular Systems Biology, ETH, Zürich, Switzerland

Search for more papers by this author
Hugo Stocker

Hugo Stocker

Institute of Molecular Systems Biology, ETH, Zürich, Switzerland

Search for more papers by this author
Mariacarla Andreozzi

Mariacarla Andreozzi

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
George N. Thalmann

George N. Thalmann

Department of Clinical Research, Urology Research Laboratory, Inselspital Bern, University of Bern, Bern, Switzerland

Search for more papers by this author
Marco G. Cecchini

Marco G. Cecchini

Department of Clinical Research, Urology Research Laboratory, Inselspital Bern, University of Bern, Bern, Switzerland

Search for more papers by this author
Tobias Zellweger

Tobias Zellweger

Division of Urology, St. Claraspital, Basel, Switzerland

Search for more papers by this author
Susanna Stürm

Susanna Stürm

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Pasi A. Koivisto

Pasi A. Koivisto

Departments of Neurology, Seinäjoki and Vaasa Central Hospitals, Seinäjoki, Finland

Search for more papers by this author
Heikki J. Helin

Heikki J. Helin

Division of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland

Search for more papers by this author
Edward P. Gelmann

Edward P. Gelmann

Herbert Irving Comprehensive Cancer Center, Columbia University, New York

Search for more papers by this author
Andrew G. Glass

Andrew G. Glass

Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon

Search for more papers by this author
Thomas C. Gasser

Thomas C. Gasser

Division of Urology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Luigi M. Terracciano

Luigi M. Terracciano

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Alexander Bachmann

Alexander Bachmann

Division of Urology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Stephen Wyler

Stephen Wyler

Division of Urology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Lukas Bubendorf

Lukas Bubendorf

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Search for more papers by this author
Cyrill A. Rentsch

Corresponding Author

Cyrill A. Rentsch

Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

Division of Urology, University Hospital Basel, University of Basel, Basel, Switzerland

Division of Urology, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland.Search for more papers by this author
First published: 02 April 2012
Citations: 19

Christian Ruiz and Martin Oeggerli contributed equally to this work.

The authors have nothing to disclose and have no conflicts of interest.

Abstract

BACKGROUND

We recently established the rationale that NRBP1 (nuclear receptor binding protein 1) has a potential growth-promoting role in cell biology. NRBP1 interacts directly with TSC-22, a potential tumor suppressor gene that is differently expressed in prostate cancer. Consequently, we analyzed the role of NRBP1 expression in prostate cancer cell lines and its expression on prostate cancer tissue microarrays (TMA).

METHODS

The effect of NRBP1 expression on tumor cell growth was analyzed by using RNAi. NRBP1 protein expression was evaluated on two TMAs containing prostate samples from more than 1,000 patients. Associations with clinico-pathological features, the proliferation marker Ki67 and survival data were analyzed.

RESULTS

RNAi mediated silencing of NRBP1 expression in prostate cancer cell lines resulted in reduced cell growth (P < 0.05). TMA analysis revealed NRBP1 protein expression in benign prostate hyperplasia in 6% as compared to 60% in both, high-grade intraepithelial neoplasia and prostate cancer samples. Strong NRBP1 protein expression was restricted to prostate cancer and correlated with higher expression of the proliferation marker Ki67 (P < 0.05). Further, patients with strong NRBP1 protein expression showed poor clinical outcomes (P < 0.05). Analysis of matched localized cancer tissues before and after castration revealed that post-therapy-related repression of NRBP1 expression was significantly associated with better overall survival.

CONCLUSIONS

We demonstrate that expression of NRBP1 is up-regulated during the progression of prostate cancer and that high NRBP1 expression is linked with poor prognosis and enhanced tumor cell growth. Prostate 72:1678–1687, 2012. © 2012 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.